Telavancin Hydrochloride(tell ah van’ sin)
Vibativ
PREGNANCY CATEGORY C
Drug Classes
Antibiotic
Lipoglycopeptide
Therapeutic Actions
A lipoglycopeptide, a semisynthetic derivative of vancomycin, that inhibits bacterial cell-wall synthesis by interfering with the polymerization and cross-linking of peptidoglycan; binds to the bacterial membrane and disrupts membrane-barrier function, causing bacterial cell death.
Indications
Treatment of complicated skin and skin-structure infections caused by susceptible strains of gram-positive organisms (Staphylococcus aureus [including methicillin-susceptible and methicillin-resistant isolates], Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, Enterococcus faecalis [vancomycin-susceptible isolates only]); combination therapy may be indicated of gram-negative pathogens are documented or suspected
NEW INDICATION: Treatment of hospital-acquired and ventilator-assisted pneumonia caused by S. aureus when other forms of treatment are not suitable
Contraindications and Cautions
Contraindicated in known hypersensitivity to components of the drug, lactation, pregnancy.
Use cautiously with renal impairment, QTc-interval prolongation or risk of prolongation.
Available Forms
Single-use vials—250, 750 mg
Dosages
Adults
10 mg/kg IV infused over 60 min once every 24 hr for 7–14 days.
Pediatric patients younger than 18 yr
Safety and efficacy not established.
Patients with renal impairment
For CrCl of more than 50 mL/min, 10 mg/kg IV every 24 hr; for CrCl of 30–50 mL/min, 7.5 mg/kg IV every 24 hr; for CrCl of 10 to less than 30 mL/min, 10 mg/kg IV every 48 hr. No recommendations are available for CrCl of less than 10 mL/min or for patients on hemodialysis.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
